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March 2009612 Tedesco et alphy, making the comparison between the two periods a
heterogeneous mix. Further limitations revolve around the
study design; this is a single center, retrospective review
initially in which the prospective portion has only been the
past 2 years. A larger, perhaps multicenter, and definitely
prospective study would be necessary to establish the rela-
tionship between these recommended procedural modifi-
cations and their effect on limiting microemboli formation
following CAS.
Furthermore, we cannot discount a learning curve ef-
fect that may have contributed to decreased microemboli
over the course of our CAS program. Of note, each of the
carotid surgeons listed here had extensive prior CAS (range
25 to 200 independent cases as primary operator) and
peripheral endovascular experience before their cases were
counted in either period 1 or period 2. While the reduction
in microemboli may simply be a reflection of improved
wire-handling skills and careful attention to the technical
aspects of the procedure, the major changes implemented
likely have contributed to the overall final effect.
In summary, despite successful performance of 47 con-
secutive CAS procedures without permanent neurologic
sequelae, there still remains a significant incidence of post-
procedure microemboli after CAS. Through implementa-
tion of quality improvement measures, there has been a
significant reduction in periprocedural embolic events as
identified via DW-MRI lesions. The long-term neurologic
and cognitive benefits associated with reduced subclinical
neurologic events remains to be determined.
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Dr Vikram Kashyap (Cleveland, Ohio). As we have heard
earlier in the Society of Vascular (SVS) meeting and earlier in this
session, the national trends for stroke after carotid artery stenting
are somewhat troubling. Dr. Tedesco and her colleagues have
rigorously applied quality improvement techniques to decreaseusing closed cell stents, systemic heparinization, and eliminating
arch arteriography. This led to a reduction in cerebral microem-
boli. I have some questions and comments for the authors.
Can you reiterate for us just the pure difference in outcomes
between open and closed cell stents? If I understood correctly,
there was about a 20% decrease in the microemboli, but that was
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Volume 49, Number 3 Tedesco et al 613not statistically significant. Do you think that this is a type 2 error
and that with increased experience that you will show that there is
a benefit in a certain stent design?
Secondly, DW-MRI is highly sensitive in picking up cerebral
lesions that do not appear to have any clinical sequelae. Is this
purely a research imaging modality or is there some clinical rele-
vance to using it?
Do you have plans or have you already acquired any late
DW-MRI imaging? This may give us some insight into the plastic-
ity of the brain.
And lastly, you have performed about 50 carotid stenting
procedures over 4 years by three operators. Can your improve-
ments in outcomes be simply increased operator experience rather
than the quality assessment techniques that you instituted?
Dr Tedesco. First, we did perform subset analysis during
period 2 to look at the isolated contribution of using the closed
cell vs the open cell system and did not find a significant
difference in the incidence or total number of microemboli. We
believe the combination of the quality improvement measures,
namely the preferential use of closed cell stents, early hepariniza-
tion, and the elimination of routine arch angiography, all contrib-
uted to the overall significant reduction in total microemboli.
Secondly, with regards to the DW-MRI lesions, we know that
they may disappear by 14 days, but we do not know the long-term
significance. Many authors have suggested since adverse neuro-
logic outcomes are so rare with carotid revascularization proce-
dures, that DW-MRI lesions can be used as a surrogate for out-
comes following CAS vs CEA in future clinical trials. We really do
not understand the clinical significance and the long-term impli-
cations of these microemboli, which may be cognitive decline, loss
of independent living, etc. We will continue to study the long-term
effects of these lesions by performing postprocedure neuropsycho-
logic testing. Furthermore, we have started performing long-term
DW-MRI imaging, at 6 months or a year to follow these patients.
The question about operator experience is an important one.
In reviewing our series, our group was past the learning curve
already prior to the initiation of our study. Each operator has
performed their 25 learning curve cases prior to the study being
initiated with pre- and postprocedure DW-MRI. So we do not
believe we are seeing improvement in technical performance solely
based on operator experience.
Dr Martin Back (Tampa, Fla). There is pretty good cardio-
thoracic literature that shows cognitive declines in patients from
microemboli that occur during cardiopulmonary bypass and open
heart surgery. Would you continue to routinely use DW-MRI in
your patients after surgery? Are abnormal findings from MRI a
potential marker for subtle neurological injury?
Dr Tedesco. Since the incidence of microemboli after CAS
has been so high, we will continue to monitor our patients that
undergo the procedure. We have now imaged more than 100
routine CEA patients without a single postprocedure microem-
boli, telling us clearly there is a difference between the procedures.
We do believe the microemboli are some sort of marker for brain
injury, and will continue to look closely at long-term effects in
these patients. We already have shown our previous work thatthose with microemboli are more likely to have transient postpro-
cedure neurologic deficits.
DrWei Zhou (Stanford, Calif). The question regarding long-
term neurocognitive effects of subclinical microemboli is an ex-
tremely important one. In fact, our next aim of this on-going study
is to examine whether subclinical microemboli persist and the long
effects of these microemboli. Our plan is to repeatMRI at 1 month
and 6 months after the procedures and to perform neuropsycho-
logical test battery at the same interval. By doing so, we hope to
understand the long-term effect of those microemboli. Again, this
is an important question. Currently, it is still a part of research
protocol, but I think eventually it may become a new outcome
standard for carotid angioplasty and stenting.
Dr James Goff (Albuquerque, NM). Most quality improve-
ment programs are driven by a procedure or process in which you
are having some problem. You nicely presented what you chose to
change, but you did not tell us why you chose those measures. Can
you tell us why you chose those performance measures?
The second question is in your period 2 patients, it looks like you
eliminated predilation of any of the carotid lesions. Butwere there any
patients in whom you did have to predilate to facilitate passage of a
protection device or to facilitate placement of the stent?
You have eliminated the arch arteriogram, but have you also
eliminated the cerebral arteriogram as well? And if you have or have
not, tell me why.
Dr Tedesco.We chose these three particular quality improve-
ment measures after careful interim analysis during our first study
published last year. By univariate analysis, the use of arch angiog-
raphy was associated with a much higher risk of microemboli,
ipsilateral and contralateral, which made some sense, and some
other authors since have confirmed in European series. For this
reason, the routine arch run was taken out of standard protocol.
We chose to heparinize earlier when we realized both hemispheres
were affected, even though we never manipulated one side, and we
began to postulate that catheter trauma along the arch, wire
manipulation, or crossing the orifices of both carotids was poten-
tially a problem. Finally, we became involved in the PROTECT
study, and began using the Abbott Xact stent more often, and
realized we were in effect switching to a closed cell stent system.
In period 2 we did not eliminate predilation. We typically
choose to predilate with a 4  20 mm balloon for all cases. With
regards to the last question, we continue to do pre- and postin-
tracranial runs (Townes view and lateral view) to assure that no
changes in flow have occurred after placement of the stent.
Dr Hasan Dosluoglu (Buffalo, NY). I am impressed at the
amount of contrast you use, 58 cc, I believe. We rarely go above 40
cc. Can this be related to repeat injections between each step
during the stenting procedure? And could these be air emboli that
you are detecting with the MRI?
Dr Tedesco. Potentially, they could be air emboli, although
we really strive to eliminate the incidence of emboli. But we have
also done analysis looking at whether or not contrast volume or
repeat injections were related to microemboli incidence and we
found no association on prior studies.
